MiNK Therapeutics, Inc. (INKT) — Financial statements
Income statement, balance sheet, and cash flow for MiNK Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.18↓15.6% | 0.22↑5.3% | 0.20↑68.1% | 0.12↑56.2% | 0.08 | |
| Gross Profit | -0.18↑15.6% | -0.22↓5.3% | -0.20↓68.1% | -0.12↓56.2% | -0.08 | |
| Operating Expenses | ||||||
| R&D Expenses | 5,757↑90768.4% | 6↓59.1% | 15↓33.0% | 23↑65.5% | 14 | |
| General & Administrative Expenses | 6,730↑56.0% | 4,314↑57955.5% | 7 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↑100.0% | -4,310 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6,730↑164092.9% | 4↓44.8% | 7↓3.6% | 8↑69.1% | 5 | |
| Other Expenses | -12,475 | 0.00↑100.0% | -0.20 | 0.00 | 0.00 | |
| Operating Expenses | 12↑17.9% | 10↓54.1% | 23↓26.3% | 31↑66.4% | 19 | |
| Total Costs & Expenses | 12↑17.2% | 11↓53.5% | 23↓25.9% | 31↑66.3% | 19 | |
| Operating Results | ||||||
| Operating Income | -12↓17.2% | -11↑53.5% | -23↑25.9% | -31↓66.3% | -19 | |
| Depreciation & Amortization | 0.18↓15.6% | 0.22↑5.3% | 0.20↑68.1% | 0.12↑56.2% | 0.08 | |
| EBITDA | -12↓16.4% | -11↑52.5% | -22↑20.2% | -28↓0.6% | -28 | |
| EBIT | -12↓15.8% | -11↑52.0% | -22↑19.8% | -28↓0.8% | -28 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.18↑4.4% | 0.17↓62.7% | 0.46 | 0.00↑100.0% | -2 | |
| Interest Income | 0.18↑4.4% | 0.17↓62.7% | 0.46↑82.9% | 0.25↑10320.5% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.25↓89.6% | 2 | |
| Non-Operating Income | 0.00↓100.0% | 0.13↑129.0% | -0.46↑84.3% | -3↓132.2% | 9 | |
| Other Income / Expenses | -0.01↑94.8% | -0.13↓129.0% | 0.46↓84.3% | 3↑125.5% | -12 | |
| Income Before Tax | -12↓15.9% | -11↑52.0% | -22↑19.8% | -28↑7.4% | -30 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↓15.9% | -11↑52.0% | -22↑19.8% | -28↑7.4% | -30 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -12↓15.9% | -11↑52.0% | -22↑19.8% | -28↑7.4% | -30 | |
| Bottom-Line Net Income | -12↓15.9% | -11↑52.0% | -22↑19.8% | -28↑7.4% | -30 | |
| EPS (Basic) | -2.93↓1.0% | -2.90↑55.7% | -6.54↑21.3% | -8.31↑8.0% | -9.03 | |
| EPS (Diluted) | -2.93↓4.6% | -2.80↑57.2% | -6.54↑21.3% | -8.31↑8.0% | -9.03 | |
| Weighted Average Shares | 4↑14.1% | 4↑9.0% | 3↑2.0% | 3↑0.6% | 3 | |
| Weighted Average Diluted Shares | 4↑10.5% | 4↑12.4% | 3↑2.0% | 3↑0.6% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.